-
1 week ago | 
hcplive.com | Abigail Brooks
The American Thoracic Society’s (ATS) International Conference took place in San Francisco, California, from May 18-21, 2025. Coined as the home of pulmonary, critical care, and sleep professionals, the 4-day conference featured the latest advances in each of these spaces, including updates on key topics in asthma, chronic obstructive pulmonary disease (COPD), lung cancer, sepsis, acute respiratory distress, sleep apnea, and more.
-
1 week ago | 
hcplive.com | Abigail Brooks
The US Food and Drug Administration (FDA) has accepted and granted priority review to Otsuka Pharmaceutical Development & Commercialization’s Biologics License Application (BLA) for sibeprenlimab for the treatment of IgA nephropathy (IgAN).1Announced on May 27, 2025, the BLA acceptance is supported by data from the phase 3 VISIONARY trial, which met its primary endpoint at the prespecified interim analysis, as well as results from the Phase 2 ENVISION clinical trial.
-
2 weeks ago | 
businessandamerica.com | Abigail Brooks
This week, Julie Eshelman has been holding her breath, waiting to see if President Donald Trump delivers on his campaign promise to make in vitro fertilization free. Eshelman is a military wife and, thanks to IVF, a mom. She first began fertility treatments in 2016, and she and her husband finally welcomed a baby girl — five years, several miscarriages and $80,000 later.
-
2 weeks ago | 
hcplive.com | Abigail Brooks
New research is shedding light on dupilumab’s sustained impact on lung function parameters in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation.1 Pooled data from the phase 3 BOREAS and NOTUS trials were presented at the American Thoracic Society (ATS) International Conference 2025 by Meilan Han, MD, MS, a professor of medicine and chief of the division of pulmonary and critical care at the University of Michigan Health.1 A fully human monoclonal antibody,...
-
2 weeks ago | 
hcplive.com | Abigail Brooks
Hydronidone met the primary endpoint in a pivotal phase 3 trial evaluating its efficacy and safety for the treatment of liver fibrosis in patients with chronic hepatitis B (CHB) in China, according to a press release from Gyre Therapeutics.1Announced on May 22, 2025, the trial met its primary endpoint for ≥1-stage regression in liver fibrosis compared to placebo.
-
2 weeks ago | 
hcplive.com | Abigail Brooks
Treatment with dupilumab (Dupixent) improves symptomatic asthma control in patients with moderate-to-severe uncontrolled asthma irrespective of the presence of coexisting chronic rhinosinusitis (CRS) and/or nasal polyposis (NP), according to findings from a recent study.1 Results from the analysis of the RAPID registry were presented at the American Thoracic Society (ATS) International Conference 2025 by Andreanne Cote, MD, MSCE, faculty of medicine at Laval University, and highlight...
-
2 weeks ago | 
hcplive.com | Abigail Brooks
Findings from a post-hoc analysis of the SURMOUNT-OSA clinical studies highlight the consistent benefit of treatment with tirzepatide in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity, regardless of their baseline OSA severity.1 The data were presented at the American Thoracic Society (ATS) International Conference 2025 by Birong Liao, PhD, and demonstrate consistent, significant improvements versus placebo in measures of OSA and cardiometabolic parameters,...
-
2 weeks ago | 
hcplive.com | Abigail Brooks
New research is shedding light on the impact of ensifentrine monotherapy on patient-reported outcomes in individuals with chronic obstructive pulmonary disease (COPD).1 Findings from the analysis of data from the phase 3 ENHANCE trials of nebulized ensifentrine were presented at the American Thoracic Society (ATS) International Conference 2025 by Michael Bradley Drummond, MD, co-medical director of UNC Pulmonary Specialty Clinics and director of the Obstructive Lung Diseases Clinical and...
-
2 weeks ago | 
hcplive.com | Abigail Brooks
New research is shedding light on real-world treatment patterns for pulmonary sarcoidosis with parenchymal involvement in the United States, highlighting high rates of glucocorticoid use and the frequent need for later-line therapies.1 The data were presented at the American Thoracic Society (ATS) International Conference 2025 by Eileen Sun, PhD, MBA, executive director of product development at aTyr Pharma, and call attention to a substantial unmet need for new treatments for pulmonary...
-
2 weeks ago | 
hcplive.com | Abigail Brooks
New research is shedding light on the prevalence of insomnia among patients admitted to the intensive care unit (ICU) with acute respiratory failure (ARF), highlighting frequent reports of sleep disturbances in this patient population.1 Study findings were presented at the American Thoracic Society (ATS) International Conference 2025 by Dexter Corlett, MD, MPH, Indiana University School of Medicine, and point to the role preexisting mental health diagnoses and a neurologic cause for ARF may...
